FIG 2.

Reasons for early palbociclib discontinuation, categorized by central study management teams as protocol-defined or non–protocol-defined, for palbociclib + ET patients by 3-month time points as presented to the IDMC in May 2020. The percentages in the 3-month periods refer to the number of patients who were still receiving palbociclib treatment up to the respective period. ^aThe increased rate of early discontinuation for nonprotocol reasons unrelated to toxicity in months 22-24 reflects administrative reasons early in the course of the study. ET, endocrine therapy; IMDC, Independent Data Monitoring Committee.